When the Biological Age Clock Lies
Does a lower epigenetic age constitute rejuvenation? This paper distinguishes analytic validity, biological relevance, functional improvement and durable clinical benefit. It explains why cellular composition and regulatory changes can move an age-associated score without repairing scarred tissue or lost circuits, and proposes an evidence hierarchy for interpreting age-reversal claims.
A measurement can improve without a person improving
DNA methylation and plasma-protein clocks can detect regularities associated with age, and some respond to interventions. But statistical predictors do not automatically measure the causal mechanism of disease. A lower clock age could reflect changes in cellular composition, inflammation, medication exposure or expression programs rather than restored structural integrity. Calling every downward movement in a clock 'rejuvenation' confuses a proxy with the outcome it was intended to help study.
Four standards of evidence
We should separate analytic validity, biological validity, functional validity and durable clinical benefit. Analytic validity means the clock reliably measures its chosen features. Biological validity asks whether those features reflect processes relevant to aging. Functional validity demands improvements in strength, cognition, mobility, organ reserve or other concrete capacities. Durable benefit asks whether such gains persist and alter meaningful disease outcomes. An epigenetic reset may pass one standard while failing another. This is especially consequential for reprogramming techniques that aim to change regulatory patterns without turning differentiated cells into pluripotent cells.
Where the mismatch comes from
Cell mixtures in blood can shift after infection or therapy. Tissue-specific clocks may behave differently from blood-derived clocks. A drug could change methylation marks without resolving extracellular fibrosis or somatic mutations. An older patient with an excellent inflammatory profile may nevertheless carry advanced joint degeneration. Conversely, a patient with unfavorable clock results might have outstanding resilience and physical function. None of these possibilities invalidates molecular clocks. They establish that a measurement needs an explicitly defined scope.
A falsifiable editorial standard
Every intervention claiming age reversal should identify the clock, the direction and magnitude of its change, whether the result replicates, and what functional outcome moved with it. Negative evidence would be a large, reproducible clock improvement accompanied by no change in functional recovery or morbidity. The Institute's proposed phrase functional rejuvenation should be reserved for the latter class of evidence, not awarded solely because a biomarker becomes numerically younger.
A clinical thought experiment
Consider a hypothetical intervention that lowers an epigenetic age estimate by three years but leaves exercise capacity, wound healing and clinical events unchanged. The honest conclusion is a favorable biomarker change, not a proven extension of healthy life. In contrast, a rehabilitation intervention might improve walking distance and independence without moving a clock at all. It would still have meaningful clinical value.
What would discriminate among explanations
The falsification target is precise: test whether a change in clock age mediates later functional improvement rather than merely accompanying it. If a clock is reproducibly changed by benign transient shifts in blood-cell composition, that component of its interpretation is weakened. If some clocks predict outcome while others disagree, the correct response is comparison and refinement, not choosing whichever score makes the intervention look best.
Selected scientific readings
- López-Otín C et al. (2023). Hallmarks of aging: An expanding universe. Cell. https://doi.org/10.1016/j.cell.2022.11.001
- Lu Y et al. (2020). Reprogramming to recover youthful epigenetic information and restore vision. Nature. https://www.nature.com/articles/s41586-020-2975-4
- Oh HSH et al. (2025). Plasma proteomics links brain and immune system aging with healthspan and longevity. Nature Medicine. https://www.nature.com/articles/s41591-025-03798-1